Contrasting ArriVent BioPharma (AVBP) & Its Rivals

ArriVent BioPharma (NASDAQ:AVBP) is one of 1,070 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare ArriVent BioPharma to related businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ArriVent BioPharma and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	0	0	5	0	3.00
ArriVent BioPharma Competitors	8271	22032	50052	1335	2.54

ArriVent BioPharma presently has a consensus price target of $39.40, suggesting a potential upside of 87.62%. As a group, “Pharmaceutical preparations” companies have a potential upside of 215.92%. Given ArriVent BioPharma’s competitors higher probable upside, analysts plainly believe ArriVent BioPharma has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

ArriVent BioPharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, ArriVent BioPharma’s competitors have a beta of 3.74, suggesting that their average share price is 274% more volatile than the S&P 500.

Profitability

This table compares ArriVent BioPharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-43.89%	-29.67%
ArriVent BioPharma Competitors	-3,399.87%	-235.11%	-32.77%

Earnings and Valuation

This table compares ArriVent BioPharma and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ArriVent BioPharma	N/A	-$69.33 million	-8.17
ArriVent BioPharma Competitors	$9.94 billion	$137.22 million	-7.59

ArriVent BioPharma’s competitors have higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

ArriVent BioPharma competitors beat ArriVent BioPharma on 8 of the 13 factors compared.

About ArriVent BioPharma

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.